Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Total Debt (2020 - 2023)

Historic Total Debt for C4 Therapeutics (CCCC) over the last 4 years, with Q2 2023 value amounting to $10.3 million.

  • C4 Therapeutics' Total Debt fell 707.61% to $10.3 million in Q2 2023 from the same period last year, while for Jun 2023 it was $10.3 million, marking a year-over-year decrease of 707.61%. This contributed to the annual value of $11.5 million for FY2022, which is 663.08% up from last year.
  • Latest data reveals that C4 Therapeutics reported Total Debt of $10.3 million as of Q2 2023, which was down 707.61% from $10.9 million recorded in Q1 2023.
  • C4 Therapeutics' 5-year Total Debt high stood at $11.5 million for Q4 2022, and its period low was $9.9 million during Q3 2020.
  • Over the past 4 years, C4 Therapeutics' median Total Debt value was $10.7 million (recorded in 2021), while the average stood at $10.7 million.
  • Per our database at Business Quant, C4 Therapeutics' Total Debt soared by 719.85% in 2021 and then tumbled by 707.61% in 2023.
  • Quarter analysis of 4 years shows C4 Therapeutics' Total Debt stood at $10.1 million in 2020, then increased by 7.12% to $10.8 million in 2021, then increased by 6.63% to $11.5 million in 2022, then dropped by 9.99% to $10.3 million in 2023.
  • Its last three reported values are $10.3 million in Q2 2023, $10.9 million for Q1 2023, and $11.5 million during Q4 2022.